Bone marrow/stem cell transplant survivors can experience a number of skin problems after transplant. Monitoring yourself for skin abnormalities and seeking prompt treatment from a dermatologist can help relieve symptoms and prevent serious problems.

This presentation discusses psychosocial challenges that can arise before, during and after a bone marrow/stem cell transplant or CAR T-cell therapy, strategies to manage them, resources that can help, and when to consult a mental health professional.

Many patients experience significant fatigue for months or years after a stem cell transplant or CAR T-cell therapy. Learn a variety of strategies you can try to manage chronic fatigue and lessen its impact on your daily activities.

El trasplante y la terapia de células CAR T han curado y prolongado las vidas de muchísimas personas con cánceres hematológicos. Sin embargo, los sobrevivientes pueden presentar complicaciones cardiovasculares en el corto y largo plazo. Conozca cuáles son esas complicaciones y cómo prevenirlas.

People who have undergone a bone marrow or stem cell transplant have an increased risk of osteopenia (loss of bone density), osteoporosis and bone fractures. Periodic bone density tests are needed to monitor bone health so that therapies can started early to prevent or reverse bone loss.

Pueden desarrollarse nuevos cánceres después de un trasplante de células madre. Esta presentación describe qué tipos de cánceres pueden desarrollarse, los factores de riesgo y las medidas que puede tomar para prevenir y detectar nuevos cánceres después del trasplante.

Graft versus Host Disease (GVHD) is a common complication after allogeneic stem cell transplant. Learn the difference between acute and chronic GVHD and how each develops. Both standard therapies and exciting new prevention and treatment interventions are discussed.

Advanced age has traditionally been seen as prohibitive for treatments like stem cell transplants and CAR T therapy. This presentation reviews evidence that overall fitness is a crucial factor in reducing non-relapse mortality and that otherwise healthy elderly patients can have successful outcomes after transplant and CAR T-cell therapy.

La terapia de células CAR T es un tratamiento nuevo para pacientes que tienen ciertos tipos de linfoma no Hodgkin. Conozca lo que implica someterse a una terapia de células CAR T, quién es un buen candidato y los posibles resultados.

CAR T therapy (chimeric antigen receptor therapy) is a new treatment strategy that has been shown to improve patient outcomes. In this lecture, Dr. William reviews the steps involved, including T-cell collection, lymphodepleting chemotherapy, reinfusion of T-cells, and follow-up care. Potential side effects and their treatments are discussed as wel